BioData is thrilled to announce groundbreaking partnerships with NASA, the National Cancer Institute, and the American Heart Association. BioData World West and NASA GeneLab will be presenting an exclusive big data workshop and pre-conference day at NASA Ames Research Center* in Silicon Valley, California.
As microelectronics technology nears the end of exponential growth over time, known as Moore’s law, there is a renewed interest in new computing paradigms such as quantum computing. A key step in the roadmap to build a scientifically or commercially useful quantum computer will be to demonstrate its exponentially growing computing power. I will explain how a 7 by 7 array of superconducting xmon qubits with nearest-neighbor coupling, and with programmable single- and two-qubit gate with errors of about 0.2%, can execute a modest depth quantum computation that fully entangles the 49 qubits. Sampling of the resulting output can be checked against a classical simulation to demonstrate proper operation of the quantum computer and compare its system error rate with predictions. With a computation space of 2^49 = 5 x 10^14 states, the quantum computation can only be checked using the biggest supercomputers. I will show experimental data towards this demonstration from a 9 qubit adjustable-coupler “gmon” device, which implements the basic sampling algorithm of quantum supremacy for a computational (Hilbert) space of about 500. We have begun testing of the quantum supremacy chip.
|Part 1: Educating on the open targets platform|
Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.
Visit the Open Targets Platform which provides an integration of public domain data to enable target identification and prioritisation.
Generating and interpreting the data required to identify a good drug target demands a diverse set of skills, backgrounds, evidence types and technologies, which do not exist today in any single entity. Open Targets brings together expertise from four complementary institutions to systematically identify and prioritise targets from which safe and effective medicines can be developed.
Our goals are to:
Instructors and Leaders:
Ian Dunham, Scientific Director, Open Targets, EMBL-EBI
Matthew Nelson, Head of Genetics, GSK
|15:50- SpliceCore: Drug Target Discovery with Splicing AI|
Martin Akerman, CTO, Cofounder, Envisagenics
16:00- Autism Diagnostics Technologies
Andrew Stewart, CEO and Founder, Autism Diagnostics
16:10 - Mendel.AI
Karim Galil, CEO and Founder, Mendel.AI
16:20 – Elastic Genomics
Chris Probert, Founder, Elastic Genomics (in stealth mode)
16:30- Improve patient identification in cardiovascular by using machine learning – concrete case
Adrien Rousset, Innovation Manager, Amgen
16:40- Neuroscence Inc
Yasaman Soudagar, CEO and Founder, Neurescence Inc
16:50- ProteinQure Inc
Mark Fingerhuth, CEO and Founder, ProteinQure Inc